NCT07739368已完成3 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial With Ferric Maltol Capsules for the Treatment of Iron Deficiency Anemia in Subjects With Inflammatory Bowel Disease and Refractory/Intolerant to Oral Ferrous Preparations
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 122
- 试验地点
- 1
- 主要终点
- Change in Haemoglobin (Hb) Concentration From Baseline to Week 12
研究概览
简要总结
The purpose of this study is to determine whether Ferric Maltol, an oral ferric iron preparation, is safe and effective in the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease (IBD).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years at the time of signing the informed consent form, male or female;
- •UC or CD, with a Simple Clinical Colitis Activity Index (SCCAI) score < 5 or a Crohn's Disease Activity Index (CDAI) score < 220 at the screening visit;
- •Anaemia, with Hb levels tested at the screening visit as follows: Hb ≥ 85 g/L and < 110 g/L for females, Hb ≥ 85 g/L and < 120 g/L for males;
- •SIron deficiency, defined as ferritin < 30 µg/L at the screening visit, or ferritin < 100 µg/L and transferrin sa
排除标准
- •Anaemia due to any cause other than iron deficiency, including but not limited to: untreated or untreatable severe malabsorption syndrome;
- •Subjects who have received the following treatments within 12 weeks prior to randomization
- •Blood transfusion
- •Erythropoietin
- •Prolyl hydroxylase inhibitors
- •Subjects who have received the following treatments within 4 weeks prior to screening
- •Oral/intramuscular/intravenous iron preparations (including sustained-release iron preparations)
- •Immunosuppressants known to induce anaemia, including but not limited to methotrexate, cyclosporine A, or tacrolimus
- •Traditional Chinese medicine prescriptions, herbs, or proprietary Chinese medicines with blood-tonifying effects (with anaemia as an indication in the package insert)
- •Vitamin B12 or folic acid measured at the screening visit was below the lower limit of normal;
- •Subjects with known hypersensitivity or allergy to ferric maltol or any component of the investigational medicinal product;
- •Subjects with known contraindications to iron preparation therapy, such as hemochromatosis, chronic hemolytic disease, sideroblastic anaemia, thalassemia, or lead poisoning-induced anaemia;
- •Subjects with creatinine > 1.5 times the upper limit of normal measured at the screening visit;
- •Subjects with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels ≥ 5 times the upper limit of normal measured at the screening visit;
- •Subjects with severe cardiovascular, hepatic, renal, hematological, gastrointestinal, immune, endocrine, metabolic, or central nervous system diseases, which in the investigator's opinion might adversely affect the subject's safety and/or the efficacy of the investigational drug;
- •Subjects with a history of malignancy within the past 5 years, except for excised basal cell carcinoma in situ;
- •Subjects with significant neurological or psychiatric disorders leading to disorientation, memory impairment, or inability to report accurately, which might interfere with treatment compliance, study conduct, or interpretation of results (e.g., Alzheimer's disease, depression, anxiety, schizophrenia or other psychiatric disorders, alcohol or drug abuse);
- •Subjects who have participated in another interventional clinical study within 4 weeks prior to randomization or would participate during this study;
- •Subjects who are inmates of psychiatric hospitals or prisons;
- •Female subjects who are pregnant or breastfeeding;
- •Other situations deemed by the investigator as unsuitable for the patient to participate in this study.
研究组 & 干预措施
Ferric Maltol
Active Comparator
30mg capsules, taken orally twice a day
干预措施: Ferric Maltol (Drug)
结局指标
主要结局
Change in Haemoglobin (Hb) Concentration From Baseline to Week 12
时间窗: Baseline to Week 12
Primary efficacy endpoint, defined as the change in Hb concentration from Baseline to Week 12. Baseline was defined as the pre-dose Hb concentration measured at the Randomisation Visit. A mixed-effects model for repeated measures (MMRM) was used for the statistical analysis of the change in Hb from baseline after treatment. The model used the change in Hb from baseline at each post-treatment time point as the dependent variable, baseline Hb as a covariate, treatment group, visit, disease at screening (UC or CD), treatment group × visit interaction, and baseline Hb × visit interaction as fixed effects, and subject as a random effect.
次要结局
- Changes in Total Iron-binding Capacity From Baseline to Week 12(Baseline to Week 12)
- Change in Transferrin Saturation From Baseline to Week 12(Baseline to Week 12)
- Change in Soluble Transferrin Receptor from Baseline to Week 12(Baseline to Week 12)
- Proportion of Subjects That Achieved ≥10 g/L Change From Baseline in Hb Concentration at Week 12(Baseline to Week 12)
- Changes in Transferrin From Baseline to Week 12(Baseline to Week 12)
- Proportion of Subjects That Achieved ≥20 g/L Change From Baseline in Hb Concentration at Week 12(Baseline to Week 12)
- Proportion of subjects with Hb concentration within the normal range at Week 12(Baseline to Week 12)
- Change in Hb concentration from baseline to Week 4(Baseline to Week 4)
- Change in Hb concentration from baseline to Week 8(Baseline to Week 8)
- Change in Serum Iron Concentration From Baseline to Week 12(Baseline to Week 12)
- Change in Serum Ferritin Concentration From Baseline to Week 12(Baseline to Week 12)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2/3 期
Bioequivalence study of Ferric carboxymaltose solution in patients with iron deficiency anemia.CTRI/2024/02/062551DifGen Pharmaceuticals LLC,104
招募中
4 期
Efficacy and Tolerability of Sucrosomial® Iron vs Ferric Maltol in Iron Deficient WomenAnemiaAnemiaIron Deficiency Anemia (IDA)NCT07308769Pharmanutra S.p.a.146
招募中
4 期
Clinical trial assessing the effect of intravenous versus oral iron supplementation on physical performance, quality of life and cognitive function in elderly frail iron deficient individuals with cardiovascular diseaseFrailty with Iron Deficiency in Elderly Patients with Cardiovascular Disease2025-521570-34-00Wroclaw Medical University396
已完成
Phase 3 4
A clinical trial comparing the efficacy of daily dosing vs alternate day dosing of iron sulfate To evaluate the effectiveness of oral Ferrous sulfate 300 mg (60 mg elemental iron) once daily versus every other day to improve hemoglobin at 12 weeks post-initiation in iron deficiency anemia patients.CTRI/2024/06/068631Aiims Raipur60
招募中
3 期
Prospective analysis of the therapeutic efficacy of iron isomaltoside in combination with or without dopaminergic therapy in patients with restless legs syndrome2024-512117-40-00Medizinische Universitaet Innsbruck140